NEWSROOM | Galderma

Galderma announces departure of its Chief Financial Officer

Galderma initiates two new clinical trials investigating nemolizumab in patients with Systemic Sclerosis and Chronic Pruritus of Unknown Origin

Breaking through the surface of sensitive skin

Acne Awareness Month: let’s talk about acne

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years

Galderma establishes new U.S. headquarters in Miami and strengthens regional leadership

RAD 2025: Long-term data on Nemluvio® (nemolizumab) demonstrate its favorable safety profile and sustained and increased improvements in itch and skin lesions in patients with atopic dermatitis up to two years

Revolutionizing Atopic Dermatitis 2025 Conference: Galderma’s Scientific Presentations

International Congress of Dermatology 2025: Galderma’s Scientific Presentations

Galderma buys back shares worth CHF 233 million in the context of accelerated bookbuild offering

Galderma intends to buy back approximately 2.4 million shares in the context of the accelerated bookbuild offering by EQT, ADIA and Auba

Galderma delivers record first quarter net sales of 1.129 billion USD, including strong performance from two launches with blockbuster potential, and confirms full-year guidance